Successful Phase 1 results for cardiometabolic disease drug PXS-4728A
22 September 2015 | By Victoria White
PXS-4728A is a highly selective inhibitor of an enzyme and adhesion protein which reduces inflammation and oxidative stress...
List view / Grid view
22 September 2015 | By Victoria White
PXS-4728A is a highly selective inhibitor of an enzyme and adhesion protein which reduces inflammation and oxidative stress...
18 May 2015 | By Victoria White
Boehringer Ingelheim has acquired Pharmaxis’ investigational drug PXS4728A, to develop it for the treatment of NASH and to prevent its consequences...